# Does a Lifetime of It Change Anything?

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-27

Canonical page: https://glpwatchdog.org/research/does-a-lifetime-of-it-change-anything

> People who have carried excess weight since childhood often assume a drug will not work for them. Across 3,782 participants in three trials, obesity beginning before age 25 made no difference to the response.

## Key points

- −23% vs −22% body weight, with similar improvements on every other measure.
- Early-onset participants had lived with obesity twice as long: 20 years against 11.
- Baseline paradox: MORE adiposity and BETTER blood sugar, lipids and blood pressure.
- The likely explanation is age, and the analysis does not say whether it adjusted for it.
- Duration, family history and known genetic causes all fail to predict response. Persistence does.

People who have carried excess weight since childhood often assume a drug will not work for them, that something about their weight is more entrenched, more constitutional, less reversible. An analysis of 3,782 participants across three trials tested that directly. Those whose obesity began **before age 25** lost 23% of their body weight on tirzepatide. Those whose began later lost 22%.[1]

## The comparison

Participants in SURMOUNT-1, [SURMOUNT-3](https://glpwatchdog.org/research/trials/surmount-3) and SURMOUNT-4 were divided by whether their obesity was diagnosed before or after age 25, and followed for 72 weeks. The early-onset group had lived with it for a mean of **20 years** against 11.

*Change at 72 weeks on tirzepatide, early-onset against later-onset obesity.[1]*

| Measure | Early onset | Later onset |
| --- | --- | --- |
| Body weight | −23% | −22% |
| Waist circumference | −22 cm | −19 cm |
| HbA1c | −0.51% | −0.52% |
| Triglycerides | −32% | −31% |
| Systolic blood pressure | −8 mmHg | −8 mmHg |

> Twice the duration, and no penalty on any measure.

The same pattern held across all three trials. Whatever else two decades of obesity does, it does not appear to blunt the response to this drug. That is a specific piece of reassurance for a group that is often told, or tells itself, the opposite.

## The paradox at baseline, and the confounder in it

The two groups did *not* start in the same place, and the differences run in unexpected directions.

*Baseline characteristics. All differences at P ≤ 0.004.[1]*

|   | Early onset | Later onset |
| --- | --- | --- |
| Obesity duration | 20 ± 12 years | 11 ± 8 years |
| BMI | **40 ± 7** | 37 ± 6 |
| Waist circumference | **118 ± 16 cm** | 112 ± 14 cm |
| HbA1c | **5.48%** | 5.60% |
| Triglycerides | **120 mg/dL** | 130 mg/dL |
| Systolic blood pressure | **121 mmHg** | 125 mmHg |

The early-onset group had more adiposity on both measures, and *better* blood sugar, triglycerides and blood pressure. The authors describe it as a mixed metabolic profile, which it is.

> **There is an obvious explanation the abstract does not address: age.** Someone whose obesity began before 25 is likely to be younger at enrollment than someone whose began later, and younger people have better blood pressure and lipids regardless of anything else. Whether the analysis adjusted for age is not stated, and until it is, the “paradox” may simply be an age difference.

If it survives adjustment, it would be interesting, because it would suggest that adiposity acquired young is somehow less metabolically damaging per unit than adiposity acquired later. That is a real hypothesis, and this analysis does not establish it.

## What it is good for

- **It answers a question people carry into the appointment.** Long-standing obesity does not predict a worse response, on this evidence.
- **It is post hoc**, splitting trials by a characteristic they were not designed around.
- **Age at diagnosis is self-reported** and imprecise in a way that blurs the boundary between the groups.
- **Funded by Eli Lilly**, which makes tirzepatide.

It also sits alongside two other findings on who responds. Rare genetic causes of obesity did not reduce response either (see [genetics caused it and the drug still worked](https://glpwatchdog.org/research/genetics-caused-it-and-the-drug-still-worked)). And common genetic variants shift expected weight loss by well under a kilogram (see [the genetics are real, and small](https://glpwatchdog.org/research/the-genetics-are-real-and-small)).

Put together, the things people expect to predict a poor response mostly do not: how long you have had it, whether it runs in your family, whether there is a genetic cause. What does predict outcome, on the evidence in this corpus, is whether someone is [still taking the drug a year later](https://glpwatchdog.org/research/less-than-half-are-still-taking-it).

## Frequently asked questions

### Do these drugs work as well if you have had obesity since childhood?

On this evidence, yes. Across 3,782 participants in three trials, those whose obesity began before age 25 lost 23% of their body weight on tirzepatide against 22% for later onset, with similar improvements on every other measure.

### Did the two groups start out the same?

No. The early-onset group had lived with obesity for twice as long, and had higher BMI and waist circumference but lower HbA1c, triglycerides and blood pressure.

### How can more adiposity come with better metabolic markers?

The likeliest explanation is age. Someone whose obesity began before 25 is probably younger at enrollment, and younger people have better blood pressure and lipids regardless. The analysis does not state whether it adjusted for age.

### What does predict a poor response then?

Not duration, and not the genetic causes that have been examined. What predicts outcome most strongly in the available evidence is whether someone is still taking the drug a year later, and in real-world cohorts fewer than half are.

### How reliable is this analysis?

It is a post hoc split of trials not designed around age of onset, using self-reported diagnosis age, funded by the drug's manufacturer. The consistency across three separate trials is what makes it worth reporting.

## References

1. Gourgari E, Srivastava G, Kelly AS, et al. Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials. Obesity. 2025. PMID: 40717199. https://pubmed.ncbi.nlm.nih.gov/40717199/

---

Cite as: GLP Watchdog, Nora Bissett, "Does a Lifetime of It Change Anything?", published 2026-08-20, updated 2026-10-27. https://glpwatchdog.org/research/does-a-lifetime-of-it-change-anything

Canonical HTML page: https://glpwatchdog.org/research/does-a-lifetime-of-it-change-anything

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
